
Home » WYETH MOVES CLOSER TO SETTLING FEN-PHEN LAWSUITS
WYETH MOVES CLOSER TO SETTLING FEN-PHEN LAWSUITS
Final judicial approval has been given to an amendment to Wyeth's national legal settlement related to fen-phen, clearing the way for the company to settle with the largest group of people who took the diet drugs fen-phen.
Under the so-called "Seventh Amendment," Wyeth will deposit $1.275 billion into a supplemental fund to be distributed on a pro rata basis to members of the matrix I and II claims, which are the least serious but most numerous claims in the settlement. The claimants first have to pass a medical review and meet other requirements.
The claimants are former users of Pondium (fenfluramine) and Redux (dexphenfluramine), two Wyeth drugs used in the fen-phen diet treatment. The drugs were recalled in 1997 after research showed they might cause heart valve damage and a fatal lung condition.
It its most recent SEC quarterly filing, Wyeth said that as of March 31, 2006, approximately 41,000 individuals have filed lawsuits against the company.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep
-
11Oct